Diversity, Equity and Inclusion:
Forbes Magazine Ranks Global Biotech Leader CSL Among America’s Best Employers for 2022
Forbes Magazine has named global biotechnology leader CSL among America’s Best Employers for 2022.
Promising Futures Scholarship program
We believe in the power of education to create opportunities and change peoples’ lives. CSL launched its Promising Futures Scholarship program in the US two years ago to provide financial assistance to employees and their dependents for technical school, vocational school, two- and four-year colleges or advanced education. The program was specifically designed to support individuals from traditionally underprivileged, under-represented communities – those who have had to overcome substantial obstacles to pursue their studies or first-generation college students. Thanks to the overwhelmingly positive response to the U.S. program, we expanded and introduced the program to include Australia this year.
Our long term gender targets:
We have set a People Manager target of 50% female representation and will continue to pursue this target and look to achieve it by 2025. For Senior Executives, we have set a target of 40% female representation by 2030.
Carbon Reduction Targets:
In alignment with Science Based Targets initiative, we commit to a 40% reduction in absolute Scope 1 and 2 emissions by 2030, using the average of CSL’s FY19-21 emissions as the basis. Further, we intend to ensure that suppliers who contribute 67% of our Scope 3 emissions have set Science Based Targets aligned Scope 1 and Scope 2 reductions by 2030.
While we strive to save and improve the lives of our patients and protect public health, we’ve taken actions to proactively mitigate and adapt to climate change. Our recent efforts include undertaking enterprise-wide climate risk and opportunity assessments in 2019/20 and 2021/22 using the IPCC Fifth and Sixth Assessment Reports (IPCC AR5 and
IPCC AR6) across our plasma centres, critical suppliers, manufacturing facilities and warehouses, disclosing against the CDP (formerly known as Carbon Disclosure Project) framework, and developing a decarbonisation roadmap.
Compared with the prior year, modest increases were experienced across energy consumption, greenhouse gas emissions and water consumption. These increases are largely due to fluctuating manufacturing volumes and commissioning activities across new infrastructure.
Access & Affordability:
In 2021/22, CSL’s investment for humanitarian access programs and product support initiatives totaled US$17.8 million.* In the US, access programs are critical to patients who are uninsured, underinsured or who cannot afford therapy.
New Humanitarian Aid partnership
In May 2022, CSL Behring announced a ground breaking new partnership with the World Federation of Hemophilia (WFH). Commencing in 2023, CSL Behring will donate 500 million international units (IUs) of coagulation factor therapy to the WFH as part of its continued support of the WFH Humanitarian Aid Program. The donation, which includes product specifically manufactured for the purposes of being donated, will create consistent and reliable access to treatment for people living with bleeding disorders in more than 60 developing countries.